Targeted Oncology Therapeutics – Hematology Cancers


targeted therapeutics leukemia indications  TARGETED ONCOLOGY THERAPEUTICS – Hematology Cancers

  LML338K October 2021 • US$6,850 


 

There is a strong trend in oncology toward therapeutics that focus on specific targeting mechanisms to achieve positive outcomes. More than three dozen targeted treatments, using novel pathways and signaling, have achieved results that represent a new era in oncology and antineoplastic therapeutics. Several targeted therapeutics indications, using novel pathways and signaling, have achieved results that represent a new era in oncology and antineoplastic therapeutics. Their success has attracted a growing number of drug developers anxious to profit from therapies that can ease the physical, psychological and emotional burden of Leukemias and related blood cancers. This report examines two dozen targeted therapeutics leukemia indications including therapeutic drugs targeting leukemias, and their mechanisms of action.

 

Targeted oncology hematology cancers

 

 targeted therapeutics leukemia indications

 

targeted oncology hematology cancers
 

  Click HERE to Order Online

 

Target Oncology Hematology Cancers – What You Will Learn

• What is the market share of approved hematology cancer therapeutics?
• What is the global supply picture for targeted hematology cancer therapeutics?
• Who are the market leaders, by Indication? by Product?
• What is the therapeutic coverage across all oncology indications? What are the product opportunities?
• What are the established products in this space? by target, indication, API class, revenue?
• What is the competitive picture for the hematology cancer market segments?
• Drug treatment resources
• Competitive therapy map
• Clinical trial activity
• Who are the leading competitors in the field of next-generation hematology cancer therapeutics?


 

Targeted Oncology Hematology Cancers – Summary of Contents

 Executive Summary

Targeted Oncology Therapeutics

Hematology Cancers

Executive Summary

The Recombinant Drug Ecosystem

mAbs and Targeted Oncology Therapeutics

Leukemias

Acute Lymphocytic Leukemia

Chronic Lymphocytic Leukemia

Childhood Acute Lymphoblastic Leukemia

Acute Myeloid Leukemia

Chronic Myelogenous Leukemia

Lymphomas

Hodgkin Lymphoma

Non-Hodgkin’s Lymphoma

Multiple Myeloma

Biological Drugs for Hematology Cancers

Monoclonal Antibodies (Twelve Therapeutic Products)

Tyrosine Kinase Inhibitors

ALL with Philadelphia chromosome (Ph+ ALL)

FDA Approved TKIs (Six Therapeutic Products)

Chimeric Antigen Receptor-T (CAR-T) (Five Products)

The Therapeutic Market Landscape

Diagnostic Tools

Drugs in Development – The Clinical Trial Picture

Leukemias

Lymphomas

Myeloma

FDA-Approved Targeted Oncology

Therapeutics for Hematology Cancers